Over 80% of the patients with prostate cancer (PCa) develop bone metastasis, which seriously affects the patients' quality of life and remains a major cause of morbidity. Radium-223 (Ra-223), a newly approved agent targeting bone metastasis of PCa, can improve the quality of life and prolong the overall survival of the PCa patients with bone metastasis. This article presents an overview of the clinical trials recently published on the management of bone metastasis of PCa with Ra-223.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
bone metastasis
20
quality life
8
metastasis pca
8
bone
5
metastasis
5
[radium-223 treatment
4
treatment bone
4
metastasis prostate
4
prostate cancer]
4
cancer] 80%
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!